🚀 VC round data is live in beta, check it out!
Galderma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Galderma and similar public comparables like Bayer, Reckitt, Haleon, Hindustan Unilever and more.
Galderma Overview
About Galderma
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs around 7,00 people.
Founded
1981
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$48B
Galderma Financials
Galderma reported last 12-month revenue of $6B and EBITDA of $1B.
In the same LTM period, Galderma generated $4B in gross profit, $1B in EBITDA, and $709M in net income.
Revenue (LTM)
Galderma P&L
In the most recent fiscal year, Galderma reported revenue of $5B and EBITDA of $1B.
Galderma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $709M | XXX | $613M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Galderma Stock Performance
Galderma has current market cap of $46B, and enterprise value of $48B.
Market Cap Evolution
Galderma's stock price is $197.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48B | $46B | -1.4% | XXX | XXX | XXX | $2.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGalderma Valuation Multiples
Galderma trades at 8.7x EV/Revenue multiple, and 36.3x EV/EBITDA.
EV / Revenue (LTM)
Galderma Financial Valuation Multiples
As of April 21, 2026, Galderma has market cap of $46B and EV of $48B.
Equity research analysts estimate Galderma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Galderma has a P/E ratio of 65.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46B | XXX | $46B | XXX | XXX | XXX |
| EV (current) | $48B | XXX | $48B | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | 36.3x | XXX | 40.0x | XXX | XXX | XXX |
| EV/EBIT | 43.0x | XXX | 48.5x | XXX | XXX | XXX |
| EV/Gross Profit | 12.4x | XXX | 13.4x | XXX | XXX | XXX |
| P/E | 65.4x | XXX | 75.7x | XXX | XXX | XXX |
| EV/FCF | 50.7x | XXX | 46.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Galderma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Galderma Margins & Growth Rates
Galderma's revenue in the last 12 month grew by 19%.
Galderma's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Galderma's rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Galderma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 46% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Galderma Public Comps
See public comps and valuation multiples for other Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Galderma | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer | XXX | XXX | XXX | XXX | XXX | XXX |
| Reckitt | XXX | XXX | XXX | XXX | XXX | XXX |
| Haleon | XXX | XXX | XXX | XXX | XXX | XXX |
| Hindustan Unilever | XXX | XXX | XXX | XXX | XXX | XXX |
| Kenvue | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Galderma M&A Activity
Galderma acquired XXX companies to date.
Last acquisition by Galderma was on XXXXXXXX, XXXXX. Galderma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Galderma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGalderma Investment Activity
Galderma invested in XXX companies to date.
Galderma made its latest investment on XXXXXXXX, XXXXX. Galderma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Galderma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Galderma
| When was Galderma founded? | Galderma was founded in 1981. |
| Where is Galderma headquartered? | Galderma is headquartered in Switzerland. |
| Is Galderma publicly listed? | Yes, Galderma is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Galderma? | Galderma trades under GALD ticker. |
| When did Galderma go public? | Galderma went public in 2024. |
| Who are competitors of Galderma? | Galderma main competitors are Bayer, Reckitt, Haleon, Hindustan Unilever. |
| What is the current market cap of Galderma? | Galderma's current market cap is $46B. |
| What is the current revenue of Galderma? | Galderma's last 12 months revenue is $6B. |
| What is the current revenue growth of Galderma? | Galderma revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Galderma? | Current revenue multiple of Galderma is 8.7x. |
| Is Galderma profitable? | Yes, Galderma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Galderma? | Galderma's last 12 months EBITDA is $1B. |
| What is Galderma's EBITDA margin? | Galderma's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Galderma? | Current EBITDA multiple of Galderma is 36.3x. |
| What is the current FCF of Galderma? | Galderma's last 12 months FCF is $954M. |
| What is Galderma's FCF margin? | Galderma's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Galderma? | Current FCF multiple of Galderma is 50.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.